:: Volume 3, Issue 8 (Winter 2017) ::
Caspian.J.Neurol.Sci 2017, 3(8): 46-53 Back to browse issues page
B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease
David Lyman
MPH retired, Department of Family Medicine, University of Tennessee, Jackson, Tennessee; dlymanmdmph@gmail.com
Abstract:   (497 Views)

The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells.

Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases characterized by excessive B cells, overactive B cells, or dysfunctional B cells.

The connective tissue diseases and vasculitis mediated by B cell may cause various disorders of the peripheral nervous system especially axonal neuropathy. B cell–directed therapies may represent a promising new treatment for autoimmune axonal neuropathies.

Keywords: B cell, Therapy, Giant Axonal Neuropathy, Mixed Connective Tissue Disease
Full-Text [PDF 587 kb]   (234 Downloads) |   |   Full-Text (HTML)  (176 Views)  
Type of Study: Review | Subject: Special

DOI: 10.18869/acadpub.cjns.3.8.46

XML     Print

Volume 3, Issue 8 (Winter 2017) Back to browse issues page